Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Wadud Z, Chintakayala P. Personal carbon trading: trade-off and complementarity between in-home and transport related emissions reduction. Ecol Econ. 2019 Feb;156:397-408. doi: 10.1016/j.ecolecon.2018.10.016
Van Houtven G, Mansfield C, Phaneuf DJ, von Haefen R, Milstead B, Kenney MA, Reckhow KH. Combining expert elicitation and stated-preference methods to value ecosystem services from improved lake water quality. Ecol Econ. 2014 Mar;99:40-52. doi: 10.1016/j.ecolecon.2013.12.018.
Bristow AL, Wardman M, Zanni AM, Chintakayala PK. Public acceptability of personal carbon trading and carbon tax. Ecol Econ. 2010 Jul 15;69(9):1824-37. doi: 10.1016/j.ecolecon.2010.04.021